The feasibility of Steady state CBV mapping using ferumoxytol immediately after Gadolinium enhanced MRI of the CNS
The goal of the study is to test if steady state CBV mapping with ferumoxytol is feasible shortly after gadolinium enhanced MRI. The study will assess if there are confounding effects of the two contrast agents when both are administered during the same imaging session.
Subjects must have neurological findings (i.e. loss of consciousness, paresis, cranial neuropathy, etc.), and/or radiological abnormalities in the brain (neoplastic or non-neoplastic in nature).
1. Subjects must have neurological findings (i.e. loss of consciousness, paresis, cranial neuropathy, etc.), and/or radiological abnormalities in the brain (neoplastic or non-neoplastic in nature).
2. Subjects must be able to undergo MRI imaging without anesthesia.
3. Subjects must be at least 10 years of age.
4. All subjects, or their legal guardians, must sign a written informed consent and HIPAA authorization in accordance with institutional guidelines.
5. Subjects with a calculated GFR > 60 mL/min/1.73 m2. (Calculation must be done using the National Kidney Disease Education Program’s website http://nkdep.nih.gov/lab-evaluation/gfr-calculators/adults-conventional-unit.asp )
6. Sexually active women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; surgical intervention i.e. tubal ligation or vasectomy; post-menopausal < 6 months; or abstinence) for at least two months after each cycle of the study. Should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
10 - 90
Healthy Volunteers Needed
Duration of Participation
Subject may complete a total of 5 study visits consisting of at least 1 day of imaging within 5 years of enrollment.
Research Nurse Jenny Firkins, RN